Maura Gillison, MD
Enriched profileProfessor of Medicine, Department of Thoracic/Head and Neck Medical Oncology (last-held title; Dr. Gillison died June 21, 2026) · The University of Texas MD Anderson Cancer Center
Maura Gillison is Professor of Medicine, Department of Thoracic/Head and Neck Medical Oncology (last-held title; Dr. Gillison died June 21, 2026) at The University of Texas MD Anderson Cancer Center. OpenAlex indexes 625 publications with 60,454 citations (h-index 98); ClinicalTrials.gov lists 6 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Medical Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Maura Gillison, MD, is Professor of Medicine, Department of Thoracic/Head and Neck Medical Oncology (last-held title at The University of Texas MD Anderson Cancer Center. The public record shows 625 publications with 60,454 citations (h-index 98), centered on Head and Neck Cancer Studies, Cervical Cancer and HPV Research, Cancer Immunotherapy and Biomarkers. It also documents an investigator role on 6 registered clinical trials, industry payments reported by 16 companies.
- Most recent indexed publication: 2026 · Cancer immunology research
- Top research focus: Head and Neck Cancer Studies
- 6 registered trials on ClinicalTrials.gov
- Open Payments reporting from 16 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 14 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 225.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Public positions
sourced statements on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →statnews.com ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 6 registered studies on ClinicalTrials.gov. The most recent:
- Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin
Sponsor: National Cancer Institute (NCI)
- Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer
Sponsor: Radiation Therapy Oncology Group
Industry payments
Updated 27 Aug 2026
16 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year20257 payments
- Merck Sharp & Dohme LLCProgram year20251 payment
- Day One BiopharmaceuticalsProgram year20251 payment
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
61.3%Serotonin-3 Receptor Antagonist61.3%Ondansetron Hcl100%Part D<11 patientsHormonal (systemic)
38.7%l-Thyroxine38.7%Levothyroxine Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 27 Aug 2026
79 congress contributions (2007–2026) across AACR, ASCO, ASH, ASTRO, ESMO per OpenAlex. The most recent:
- Abstract LB485: Integrative analyses of cervical cancer and patient-derived organoids uncover signaling and metabolic circuits associated with therapy-resistant
AACR Annual Meeting
AACR2026Co-authorLate-breaking - Abstract 37: Characterization of cervical cancer patient derived organoid
AACR Annual Meeting
AACR2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- FOXM1-Specific TCR-Engineered T Cells Target Non-Small Cell Lung Cancer.
Cancer immunology research
Article2026 - The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial.
Cancer research communications
Clinical Trial2026 - Human Papillomavirus Integration Induces Oncogenic Host Gene Fusions in Oropharyngeal Cancers.
Cancer discovery
Article2025 - Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade.
Cancer discovery
Clinical Trial2025 - LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC.
Future oncology (London, England)
Article2025
Most-cited works
by citation count (OpenAlex)- 01Human Papillomavirus and Survival of Patients with Oropharyngeal CancerArticle6,569 citations2010
- 02Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckArticle5,112 citations2016
- 03Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United StatesArticle3,624 citations2011
- 04Evidence for a Causal Association Between Human Papillomavirus and a Subset of Head and Neck CancersArticle3,113 citations2000
- 05Case–Control Study of Human Papillomavirus and Oropharyngeal CancerArticle2,697 citations2007
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- ResearchGate
researchgate.net/scientific-contributions/Maura-L-Gillison-39494323
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- X / Twitter
twitter.com/mdandersonnews/status/849008194588471296
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →twitter.com ↗ - YouTube
youtu.be/lXMjHc66d6E
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtu.be ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancerletter.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancerletter.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗
- Board Certified
Medical Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doctor.webmd.com ↗
Editorial & leadership roles
journal and society appointments- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →faculty.mdanderson.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancerletter.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cprit.texas.gov ↗
- Formerly Jeg Coughlin Chair in Cancer Research and faculty member
The Ohio State University Comprehensive Cancer Center
2017provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancerletter.com ↗
- Profile feature
"Maura L. Gillison, MD, PhD, Pioneer in HPV-Related Head and Neck Cancer, Has Often Changed Lanes in Her Career" - The ASCO Post
2019verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - ASCO Daily News video interview
"Karnofsky Memorial Award Winner Dr. Maura L. Gillison Highlights Areas of Unmet Need in HPV-Associated Cancers"
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dailynews.ascopubs.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center